NCT04684420View on ClinicalTrials.gov

GXR RM (Glucophage® Extended Release Reduced Mass) 500 Milligram (mg) Korea Bioequivalence (BE) Study

PHASE1CompletedINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

December 22, 2020

Primary Completion Date

March 11, 2022

Study Completion Date

March 11, 2022

Conditions
Healthy
Interventions
DRUG

Glucophage® XR RM Test

Participants received a single oral dose of 500 mg of test Glucophage® XR RM tablet under fasting or fed conditions.

DRUG

Glucophage® XR Reference

Participants received a single oral dose of 500 mg of reference Glucophage® XR tablet under fasting or fed conditions.

Trial Locations (1)

35015

Clinical Trials Center, Chungnam National University Hospital, Daejeon

All Listed Sponsors
lead

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

INDUSTRY

NCT04684420 - GXR RM (Glucophage® Extended Release Reduced Mass) 500 Milligram (mg) Korea Bioequivalence (BE) Study | Biotech Hunter | Biotech Hunter